window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical & Regulatory

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ARTCLINE completes enrolment in septic shock trial for ARTICE therapy

    ARTCLINE has completed patient enrolment in a 142-patient randomized study [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline

    Neomorph has closed a $100 million Series B financing to [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE expands Lokelma access for hyperkalaemia after draft recommendation

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Emalex wins US patent for ecopipam ODT as Tourette access program grows

    Emalex has secured a US patent for an orally disintegrating [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD

    MaaT Pharma has published retrospective real-world data from its CHRONOS [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed

    Kainova Therapeutics has dosed the first European patient in its [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    European liver experts highlight rising MASLD burden at EASL symposium in Budapest

    European liver disease specialists have highlighted the growing burden of [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Therapeutic Areas

    Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy

    Click Therapeutics has secured a $50M Series D investment from [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial

    Kainova Therapeutics has dosed the first patient in Europe in [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Manufacturing & Supply Chain, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top